Behavioral Weight Loss and Stigma Reduction



Status:Recruiting
Conditions:Obesity Weight Loss
Therapuetic Areas:Endocrinology
Healthy:No
Age Range:18 - Any
Updated:3/10/2019
Start Date:October 16, 2018
End Date:November 2022
Contact:Caroline Bach
Email:caroline.bach@pennmedicine.upenn.edu
Phone:215-746-7191

Use our guide to learn which trials are right for you!

A Randomized Controlled Trial of Behavioral Weight Loss and Stigma Reduction for Long-Term Weight Loss

This is a randomized controlled trial to test the effects on long-term weight loss of a novel
stigma-reduction intervention combined with standard BWL treatment, as compared to BWL alone.
Participants will be a total of 104 men and women seeking weight loss, ages 18 years and
older, with a body mass index (BMI) of 30 kg/m2 or above (or 27 kg/m2 or above with an
obesity-related comorbidity), a history of experiencing weight bias, and elevated levels of
WBI. Participants will attend a screening visit in which they will complete a behavioral
evaluation with a psychologist and a medical history that will be reviewed by a nurse
practitioner or physician. Questionnaires assessing experiences and internalization of weight
bias, with confirmation by interviewer assessment during the behavioral evaluation, will be
used to determine whether participants meet criteria for having high levels of WBI. Eligible
consenting participants will be randomly assigned to the standard BWL intervention (n = 52)
or the stigma + BWL intervention (n = 52). All participants will attend weekly, 90-minute
group meetings for 20 weeks (20 visits). In the stigma + BWL treatment group, 60 minutes will
be devoted to BWL and 30 minutes to weight stigma. In the standard BWL treatment group, the
additional 30 minutes will be devoted to sharing recipes and food preparation tips. Following
20 weeks of weight loss treatment, participants will attend group meetings focused on weight
loss maintenance, monthly from weeks 21-46 (6 visits), and every-other-month from weeks 47-72
(3 visits). Maintenance sessions in the stigma + BWL group will continue to incorporate
discussion of WBI and stigma-related barriers to physical activity. Assessments - which
include questionnaires, blood draws, and measurements of body weight and physical activity -
will occur at baseline and weeks 20, 46 (no blood draw this week), and 72. Weight will be
measured at every group meeting for clinical purposes.


Inclusion Criteria:

- Eligible participants will be men and women ages 18 years and older.

- Participants must have obesity, defined as a BMI ≥ 30 kg/m2 or ≥ 27 kg/m2 with an
obesity-related comorbidity.

o Obesity-related comorbidities (which confer added CVD risk) will include:

- coronary heart disease;

- other atherosclerotic disease;

- sleep apnea;

- hypercholesteremia (i.e., high cholesterol, as diagnosed by doctor and/or if taking
medication to lower cholesterol);

- and components of the metabolic syndrome, including hypertension (SBP ≥130, DBP ≥80 mm
Hg, diagnosed by doctor and/or if taking anti-hypertensive medication); fasting blood
glucose of 100-125 mg/dL (or prediabetes, diagnosed by doctor),; low HDL cholesterol
(<40 mg/dL in men, <50 mg/dL in women), elevated triglycerides (>150 mg/dL, i.e.,
dyslipidemia diagnosed by doctor or taking medication to treat dyslipidemia), or
elevated waist circumference (≥40 in for men, ≥35 in for women),.

- Eligible participants must also report a history of experiencing weight bias as
assessed by self-report questionnaire and in-person interview, and have elevated
levels of WBI as indicated by an average score of 4 (midpoint) or above on the Weight
Bias Internalization Scale (WBIS) and by in-person interview.

- Participants must be seeking weight loss.

- If currently taking medications, dosages must be stable for at least 3 months.

- Participants will be eligible to participate if they exhibit mild to moderate severity
of depression, anxiety, or binge eating disorder, as determined by the behavioral
evaluation and the screening measures (Beck Depression Inventory-II and Questionnaire
for Eating and Weight Patterns; see below for details). Elevated WBIS scores are often
associated with these variables.

- Participants taking anti-depressant medication will be eligible if their dose has been
stable for a minimum of 3 months.

Eligible female patients will be:

- non-pregnant and non-lactating

- surgically sterile or postmenopausal, or they will agree to continue to use a method
of birth control during the study

Participants must:

- have a PCP who is responsible for providing routine care

- have reliable telephone service and/or email access with which to be in contact with
the study team

- understand and be willing to comply with all study-related procedures and agree to
participate in the study by giving written informed consent

Exclusion Criteria:

Applicants will be excluded if they have:

- a diagnosis of type I or II diabetes (for type II diabetes, blood glucose ≥126 mg/dL
or A1C ≥6.5);

- uncontrolled hypertension (blood pressure ≥ 160/100 mm Hg);

- experienced a cardiovascular event (e.g., stroke, myocardial infarction) in the last
12 months;

- lost and maintained ≥ 5% of their initial weight in the last 3 months or ≥ 10% in the
past 2 years;

- or have participated in individual or group psychotherapy related to weight in the
last 3 months (due to the potentially confounding effects of receiving a simultaneous
cognitive-behavioral intervention).

o Participants who have recently received or are currently receiving therapy for a
pre-existing mental health issue unrelated to weight (e.g., psychotherapy for
depression or anxiety, or marriage, grief, or career counseling) may be eligible if
the therapy is deemed by the Principal Investigator to be unlikely to affect weight,
eating habits, or physical activity.

- Applicants with severe symptoms of mood (BDI-II score ≥ 29), anxiety, or binge eating
disorder, and any severity of thought or substance use disorders will not be accepted
into the study, as these symptoms may interfere with individuals' ability to adhere to
a weight loss program.

o Clinician judgment will be used to determine severity of mood disorder symptoms
independent from obesity-related concerns and complications (e.g., fatigue), and
decisions about applicants' eligibility based on psychiatric symptoms will fall within
the Principal Investigator's discretion.

- Individuals with bulimia nervosa will not be eligible to participate, because weight
loss may be contraindicated.

- Applicants with current, active suicidal ideation, and/or a suicide attempt within the
past year will be excluded from the study and referred to psychiatric treatment
facilities in the greater Philadelphia area.

- Applicants will not be eligible if they have a history of bariatric surgery.

- Women who are nursing, pregnant, or planning to become pregnant in the next 16 months
are not eligible to participate.

- Applicants who report obtaining 150 minutes or more of structured physical activity
per week (e.g., 30 minutes 5 days per week) will not be eligible, as they will already
be obtaining the recommended amount of physical activity and may not be able to
further increase their activity as part of the study.
We found this trial at
1
site
Philadelphia, Pennsylvania 19104
Principal Investigator: Rebecca L Pearl, PhD
Phone: 215-746-7191
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials